InMed Pharmaceuticals Inc.
Data quality: 100%
INM
Nasdaq
Manufacturing
Chemicals
$0.64
▼
$0.00
(-0.43%)
Mkt Cap: 1.88 M
Price
$0.64
Mkt Cap
1.88 M
Day Range
$0.58 — $0.65
52-Week Range
$0.58 — $7.98
Volume
32,467
Open $0.65
50D / 200D Avg
$0.87
25.97% below
50D / 200D Avg
$1.73
62.71% below
Quick Summary
Key Takeaways
Negative free cash flow of -7.42 M
Capital efficient — spends only 0.00% of revenue on capex
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)7.50%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-72.38%
Below sector avg (-51.02%)
ROICN/A
Net Margin-170.07%
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio5.94
Interest CoverageN/A
Valuation
PE (TTM)
-0.25
Above sector avg (-1.98)
P/B Ratio0.20
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (44 peers)
Peer Comparison
vs Manufacturing sector median (44 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -0.3 | -2.0 |
| P/B | 0.2 | 5.1 |
| ROE % | -72.4 | -51.0 |
| Net Margin % | -170.1 | -150.2 |
| Rev Growth 5Y % | — | 9.3 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 7.50% | Revenue Growth (3Y) | 9.32% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 4.51 M | Net Income (TTM) | -7.66 M |
| ROE | -72.38% | ROA | -62.43% |
| Gross Margin | 29.73% | Operating Margin | N/A |
| Net Margin | -170.07% | Free Cash Flow (TTM) | -7.42 M |
| ROIC | N/A | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 5.94 |
| Interest Coverage | N/A | Asset Turnover | 0.37 |
| Working Capital | 7.31 M | Tangible Book Value | 8.05 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.25 | Forward P/E | N/A |
| P/B Ratio | 0.20 | P/S Ratio | 0.42 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -394.85% | ||
| Market Cap | 1.88 M | Enterprise Value | -5.08 M |
| Per Share | |||
| EPS (Diluted TTM) | -2.88 | Revenue / Share | 1.54 |
| FCF / Share | -2.54 | OCF / Share | -2.54 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0.00% | FCF Conversion | 96.84% |
| SBC-Adj. FCF | -7.52 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.94 M | 4.60 M | 4.14 M | 1.09 M | — |
| Net Income | -8.16 M | -7.68 M | -7.95 M | -18.60 M | -10.20 M |
| EPS (Diluted) | -8.36 | -1.01 | -3.25 | -33.17 | — |
| Gross Profit | 1.71 M | 1.10 M | 1.40 M | 543,546.0 | — |
| Operating Income | — | — | -7.95 M | -18.60 M | — |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 2.85 M | 3.77 M | 3.73 M | 7.28 M | 5.34 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 212,839.0 | 219,600.0 | 202,249.0 | 185,657.0 | 120,866.0 |
| Interest Expense | — | — | — | -360,350.0 | — |
| Income Tax | 7,100.0 | 7,100.0 | 13,100.0 | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 15.58 M | 11.82 M | 14.11 M | 12.79 M | 9.78 M |
| Total Liabilities | 2.15 M | 2.62 M | 2.02 M | 3.71 M | 2.40 M |
| Shareholders' Equity | 13.43 M | 9.21 M | 12.09 M | 9.08 M | 7.38 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 11.08 M | 6.57 M | 8.91 M | 6.18 M | 7.36 M |
| Current Assets | 12.87 M | 8.69 M | 11.33 M | 9.60 M | 8.38 M |
| Current Liabilities | 1.84 M | 1.97 M | 2.00 M | 3.32 M | 2.22 M |
{"event":"ticker_viewed","properties":{"ticker":"INM","listing_kind":"stock","pathname":"/stocks/inm","exchange":"Nasdaq","country":"US"}}